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Introduction

Results

Chromodomain-helicase-DNA-binding
protein 1 (CHD1) is an ATP-dependent
chromatin remodeler involved in gene
transcription and organismal
development [1]. Homozygous CHD1
deletion leads to genomic instability as
well as cell phenotypic alterations and is
the second most common deletion
found in human prostate cancer (PCa)
[2-4]. KDM1/3/4 protein family are
histone demethylases that target H3K9
and H3K36 [5]. High expression of
KDMs can lead to the downregulation of
H3K9me3 and subsequent abnormal
gene activation, promoting
tumorigenesis in prostate cancer (Fig. 1)
[6, 7]. ML324 is a small-molecule
selective inhibitor of KDM4s which
reduces PCa cell proliferation [8-10].
Here, we study the crosstalk between
CHD1 and KDM4 in PCa.

Through epigenetics compound library
screening, ML324, a small-molecule
selective inhibitor of KDM4, ranked as
the most sensitive compound in WT
versus CHD1 knockout LNCaP cells
(Fig. 3A). IC50 analyses in multiple PCa
cell lines with or without CHD1 deletion
confirmed that CHD1 loss makes PCa
cells less sensitive to KDM4 inhibitor
ML324 (Fig. 3B-C). Mechanistically, we
found that CHD1 deletion reduces the
expression of KDM4A and KDM4D both
in vitro (Fig. 4) and in vivo (Fig. 5).
KDM4A and KDM4D regulate the
demethylation of H3K9, but
trimethylation levels of H3K9 did not
change with CHD1 loss in vivo (Fig. 5).
However, CHD1 deletion upregulates
KDM1A and KDM3A (Fig. 6), which also
regulates the demethylation of H3K9.
This may compensate for the reduced
KDM4A/D, resulting in the maintenance
of H3K9me3 levels.

Fig. 1 Alteration of
H3K9 methylation
states by KDM4
influences
transcriptional
regulation and
chromatin dynamics
[7].

Conclusions
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As a chromatin remodeler, CHD1 has
been found to be involved in transcription
regulation by reading H3K4me3. Here,
our study uncovered a novel function of
CHD1 in modulating KDMs. CHD1 loss
inhibits KDM4A/D while promoting
KDM1A and KDM3A, resulting in the
maintenance of H3K9me3 levels. Future
studies will focus on exploring this
relationship as well as the identification of
target genes and downstream pathways
of the CHD1-KDM axis to better
understand their function in PCa
development and progression.
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Fig. 4 CHD1 regulates KDM4A and KDM4D levels.
qPCR shows mRNA expression in LNCaP WT vs CHD1
KO cells (A). ChIP-seq shows that CHD1 binds to the
promoter regions of KDM4A and KDM4D (B). Western
Blot shows decreased KDM4A and KDM4D protein
levels in CHD1 KO lines (C). TCGA database shows
that KDM4A and CHD1 levels are highly correlated.
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Fig. 7 Proposed mechanism for CHD1-KDM axis.

1.5

normalized cell viability

Epigenetics compound library screening
was performed using LNCaP WT cells
and isogeneic CHD1 knockout cells, cell
viability was then measured using
CellTiter-Glo® Luminescent Cell
Viability Assay. The small compounds
were ranked based on the sensitivity in
WT versus CHD1 knockout cells. For
top candidates, the IC50 was
determined by measuring cell viability in
multiple PCa cell lines. RNA levels were
measured using qPCR and RNA array.
ChIP-seq was used to assess CHD1
regulation of KDM4A and KDM4D.
Protein expression and histone markers
were measured by Western Blot and
immunohistochemistry.
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Fig. 5 Immunohistochemistry of DU145 WT and CHD1
knockout tumors show a decrease in KDM4A and
KDM4D, however no apparent change in H3K9me3

Fig. 3 ML324, a selective KDM4 inhibitor, was found to
be the most sensitive compound in WT vs CHD1
knockout PCa cell lines through epigenetic compound
screening (A) and IC50 analyses (B-C)

Fig. 2 Epigenetics compound library screening process
to determine drug responsiveness in CHD1 loss
prostate cancer.
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Fig. 6 KDM1A and KDM3A RNA levels are upregulated
upon CHD1 deletion, show via RNA microarray.
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